Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

80 American Society of Anesthesiologists (ASA) grade I-II patients, 18-60 years old,scheduled for elective upper limb orthopaedic surgery under supraclavicular brachial plexus block, were included in this prospective study. The patients were randomly assigned to group R (Ropivacaine alone) and group RD (Ropivacaine and dexmedetomidine) (40 patients in each group). Group R received Ropivacaine 0.50% (30 cc) + placebo and group RD received Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 µg/kg.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Government Medical College, Haldwani
• Treatments: Dexmedetomidine; Ropivacaine

Criteria

Inclusion Criteria:

• 80 ASA Grade I and II patients of either sex, aged 18-60 years, undergoing various orthopaedic surgeries on the upper limb under supraclavicular brachial plexus block.

Exclusion Criteria:

• Patient refusal

• Patients with chronic pain (pain lasting more than 12 weeks)

• Those using chronic analgesic medications (opioid, non steroidal anti-inflammatory drugs, anticonvulsants, antidepressants)

• Coagulopathy

• History of brachial plexus injury

• Allergy to the study drugs

• Patients taking other medications with α-adrenergic blocking effect

• Hepatic or renal insufficiency

• Systemic infection or infection at the site of injection, and shoulder surgery.